i don't know what to think about this. after the realization that pyrilutamide does have systemic side effects not better than finasteride and can cause sexual side effects even though their marketing gig was that it doesnt its hard to be excited about anything from them.
> Following multiple-dose topical administration of GT20029, the mean maximum drug concentrations of all cohorts were lower than 0.05ng/mL.
nobody knows what this means. in pyrilutamide trials they also wrote something like this as if it was some high achievement but there is no reference for these numbers, nobody understands what t means to have 0.05ng/ml of a degrader in your blood.
>The pharmacokinetic results showed that the topical use of PROTAC compound could penetrate into the body, but the exposure was much lower than KX-826 (small molecule antagonist), indicating that the safety was controllable
so you have an androgen receptor degrader going systemic, the safety is "controllable" whatever that means, usually n these report everything is always "excellent" or "very safe" and not tolerable. additionally, the comparison with pyrilutamide here makes no sense as it is a completely different molecule. 1 molecule of GT20029 could degrade 1000 receptors while 1 pyr molecule could only bind to one for all we know and so the concentration in the body is not a comparable metric.
again they will develop the most advanced drug but they cant use a good vehicle to deliver it. so it causes side effects and thats the end of the story. probably developing a better vehicle would cost less in ROD then one single trial run